Dipeptidyl-Peptidase IV Inhibitor

CHICAGO — The use of real-world evidence together with randomized controlled trial data can provide further insight into the effectiveness and safety of drugs for diabetes and cardiovascular disease in real-life clinical settings, according to a speaker at the Cardiometabolic Health Congress.

Adults with early type 2 diabetes and elevated cardiovascular risk who were assigned the DPP-IV inhibitor linagliptin were no more likely to experience a CV event during 6 years of follow-up than similar adults assigned the sulfonylurea glimepiride, according to study data presented at the European Association for the Study of Diabetes annual meeting.

More health care providers prescribe metformin to patients with type 2 diabetes and chronic kidney disease than other diabetes medications, with most prescriptions coming from primary care physicians, according to findings published in the Journal of Diabetes and its Complications.

Adults with type 2 diabetes who are treated with DPP-IV inhibitors are more likely to develop pancreatitis and pancreatic cancer compared with those treated with other medications, according to findings published in Diabetes Care.

Patients with diabetes are at a substantially increased risk for CVD, which is the leading cause of health complications and death in these patients.